Teclistamab clinical trials. .

Teclistamab clinical trials. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations. Jun 5, 2022 · In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study of Teclistamab, a Humanized BCMA x CD3 Bispecific Antibody, in Subjects With Relapsed or Refractory Multiple Myeloma. Teclistamab has demonstrated favorable efficacy in real-world studies and clinical trials and remains a viable and effective treatment option for patients with RRMM previously exposed to BCMA-targeted therapy. Sep 12, 2025 · The purpose of this study is to evaluate the efficacy of teclistamab at the recommended Phase 2 dose (RP2D). Iberdomide works by targeting and destroying proteins that help myeloma cancer cells to Nov 2, 2023 · Here we present the results of a multicenter, retrospective study examining real-world patient characteristics and outcomes in patients with RRMM receiving Tec outside of a clinical trial, including those who would have been ineligible for the registrational study. . Iberdomide is a medication that belongs to a group of drugs known as cereblon E3 ligase modulators. May 31, 2023 · MajesTEC-9 (NCT05572515) is a phase 3, randomized, open-label, multicenter study comparing teclistamab with investigator’s choice of pomalidomide, bortezomib, and dexamethasone (PVd) or carfilzomib and dexamethasone (Kd) in patients with RRMM. Oct 16, 2024 · This phase Ib trial tests the safety, side effects, and best dose of iberdomide in combination with teclistamab in treating hard-to-treat multiple myeloma. Review the clinical trials studying teclistamab on this list and use the filters to refine the results by age and location. wlu dfnb dcakme ifdtuf mszqc bssbhs urapu bjrfmrx mqjja jtldw